Metformin suppresses tumor angiogenesis and enhances the chemosensitivity of gemcitabine in a genetically engineered mouse model of pancreatic cancer
The DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
Abstract
Aims: Pancreatic ductal adenocarcinoma (PDAC) is one of the most malignant diseases and has few effective and reliable therapeutic strategies. The anti‐tumor effect of metformin is widely known, however, there is only limited evidence regarding the anti‐angiogenesis effect and chemosensitization of metformin and its underlying mechanisms in PDAC. Main methods: In the present study, we adopted a spontaneous PDAC mouse model named LSL‐KrasG12D/+; Trp53fl/+; Pdx1‐Cre (KPC) mice to explore the mechanism of the modulation of tumor angiogenesis and chemosensitization of metformin by treating KPC mice with metformin, gemcitabine or a combination of the two. H&E staining, Masson staining and immunohistochemical staining were adopted to describe the histopathology and biomarkers of the KPC in different groups. Key findings: Metformin plus gemcitabine reduced tumorigenic potential of PDAC. Specifically, metformin showed an anti‐pancreatic stellate cells (PSCs) effect via decreasing the expression of sonic hedgehog (SHH) and then sparked some downstream effects, for example, inhibiting the production of vascular endothelial growth factor (VEGF) in the tumor microenvironment, reducing the formation of tumor neovascularization, attenuating the desmoplastic reaction and enhancing the antitumor effect of gemcitabine. Significance: We concluded that metformin suppressed tumor angiogenesis and enhanced the chemosensitivity of gemcitabine via inactivating PSCs in PDAC of KPC mice.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Preinvasive and invasive ductal pancreatic cancer and its early detection in the mouse
Hingorani, S. R., Petricoin, E. F., Maitra, A., Rajapakse, V., King, C., Jacobetz, M. A., Ross, S., Conrads, T. P., Veenstra, T. D., Hitt, B. A., et al. (2003) · Cancer Cell · doi:10.1016/s1535-6108(03)00309-x · Cited by 2,471
Kamisawa, T., Wood, L. D., Itoi, T., & Takaori, K. (2016) · The Lancet · doi:10.1016/s0140-6736(16)00141-0 · Cited by 2,212
Basturk, O., Hong, S.-M., Wood, L. D., Adsay, N. V., Albores-Saavedra, J., Biankin, A. V., Brosens, L. A. A., Fukushima, N., Goggins, M., Hruban, R. H., et al. (2015) · American Journal of Surgical Pathology · doi:10.1097/pas.0000000000000533 · Cited by 864
Sahra, I. B., Laurent, K., Loubat, A., Giorgetti-Peraldi, S., Colosetti, P., Auberger, P., Tanti, J. F., Le Marchand-Brustel, Y., & Bost, F. (2008) · Oncogene · doi:10.1038/sj.onc.1211024 · Cited by 861
Mutant p53 drives metastasis and overcomes growth arrest/senescence in pancreatic cancer
Morton, J. P., Timpson, P., Karim, S. A., Ridgway, R. A., Athineos, D., Doyle, B., Jamieson, N. B., Oien, K. A., Lowy, A. M., Brunton, V. G., et al. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0908428107 · Cited by 657
Desmoplastic Reaction in Pancreatic Cancer: Role of Pancreatic Stellate Cells
Apte, M. V., Park, S., Phillips, P. A., Santucci, N., Goldstein, D., Kumar, R. K., Ramm, G. A., Buchler, M., Friess, H., McCarroll, J. A., et al. (2004) · Pancreas · doi:10.1097/00006676-200410000-00002 · Cited by 591
Genetically Engineered Mouse Models: Closing the Gap between Preclinical Data and Trial Outcomes
Singh, M., Murriel, C. L., & Johnson, L. (2012) · Cancer Research · doi:10.1158/0008-5472.can-11-2786 · Cited by 125
Cited by
Targeting Mitochondrial Complex I Overcomes Chemoresistance in High OXPHOS Pancreatic Cancer
Masoud, R., Reyes-Castellanos, G., Lac, S., Garcia, J., Dou, S., Shintu, L., Abdel Hadi, N., Gicquel, T., El Kaoutari, A., Diémé, B., et al. (2020) · Cell Reports Medicine · doi:10.1016/j.xcrm.2020.100143 · Cited by 175
“In PDAC preclinical models, metformin and phenformin are both able to inhibit tumor growth,(22,23) andmetformin treatment amplifies the gemcitabineinduced delay in tumor growth through a less reactive pancreatic microenvironment.(24) Treatment of diabetic patients with metformin was described to lower the risk to deve…”
BackgroundWang, J.-C., Li, G.-Y., Wang, B., Han, S.-X., Sun, X., Jiang, Y.-N., Shen, Y.-W., Zhou, C., Feng, J., Lu, S.-Y., et al. (2019) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-019-1211-2 · Cited by 138
Self-citationA microfluidic-based PDAC organoid system reveals the impact of hypoxia in response to treatment
Geyer, M., Schreyer, D., Gaul, L.-M., Pfeffer, S., Pilarsky, C., & Queiroz, K. (2023) · Cell Death Discovery · doi:10.1038/s41420-023-01334-z · Cited by 61
McCubrey, J. A., Yang, L. V., Abrams, S. L., Steelman, L. S., Follo, M. Y., Cocco, L., Ratti, S., Martelli, A. M., Augello, G., & Cervello, M. (2022) · Cells · doi:10.3390/cells11142155 · Cited by 49
“Combined metformin and gemcitabine treatment reduced Shh expression and altered the recruitment of tumor supportive PSCs, which reduced angiogenesis [193].”
Background
Metadata
- Authors
- Qian, W., Li, J., Chen, K., Jiang, Z., Cheng, L., Zhou, C., Yan, B., Cao, J., Ma, Q., & Duan, W.
- Venue
- Life Sciences
- Publisher
- Elsevier BV
- Published
- 2018-09
- Volume
- 208
- Pages
- 253-261
- ISSN
- 0024-3205 (ISSN-L)
- OpenAlex
- W2884044632
- Cited by
- 48
- References
- 7
- FWCI
- 2.53
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Metformin suppresses tumor angiogenesis and enhances the chemosensitivity of gemcitabine in a genetically engineered mouse model of pancreatic cancer. https://app.cochat.ai/papers/10.1016/j.lfs.2018.07.046
- The paper
- Qian, W., Li, J., Chen, K., Jiang, Z., Cheng, L., Zhou, C., Yan, B., Cao, J., Ma, Q., & Duan, W. (2018). Metformin suppresses tumor angiogenesis and enhances the chemosensitivity of gemcitabine in a genetically engineered mouse model of pancreatic cancer. Life Sciences. https://doi.org/10.1016/j.lfs.2018.07.046
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.